Details

Autor(en) / Beteiligte

• Habermann, Felix-Nikolai Oschinka Jegor
• Schmitt, Daniela
• Failing, Thomas
• Fischer, Jann
• Ziegler, David Alexander
• Fischer, Laura Anna
• Alt, Niklas Josua
• Muster, Julian
• Donath, Sandra
• Hille, Andrea
• Schirmer, Markus Anton
• Guhlich, Manuel
• El Shafie, Rami A
• Rieken, Stefan
• Leu, Martin
• Dröge, Leif Hendrik

Titel

Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes

Ist Teil von

• Current oncology (Toronto), 2022-02, Vol.29 (2), p.1080-1092

Ort / Verlag

Switzerland: MDPI

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The pandemic raised a discussion about the postponement of medical interventions for non-small cell lung cancer (NSCLC). We analyzed the characteristics of pretreatment diagnostic assessment in the pandemic and the influence of diagnostic assessment on outcomes. A total of 96 patients with stereotactic body radiation therapy (SBRT) for NSCLC were included. The number of patients increased from mean 0.9 (2012-2019) to 1.45 per month in the COVID era ( < 0.05). Pandemic-related factors (contact reduction, limited intensive care unit resources) might have influenced clinical decision making towards SBRT. The time from pretreatment assessment (multidisciplinary tumor board decision, bronchoscopy, planning CT) to SBRT was longer during the COVID period ( < 0.05). Reduced services, staff shortage, or appointment management to mitigate infection risks might explain this finding. Overall survival, progression-free survival, locoregional progression-free survival, and distant progression-free survival were superior in patients who received a PET/CT scan prior to SBRT ( < 0.05). This supports that SBRT guidelines advocate the acquisition of a PET/CT scan. A longer time from PET/CT scan/conventional staging to SBRT (<10 vs. ≥10 weeks) was associated with worse locoregional control ( < 0.05). The postponement of diagnostic or therapeutic measures in the pandemic should be discussed cautiously. Patient- and tumor-related features should be evaluated in detail.